Author

@FiercePharma FiercePharma

grade Bcorporatex.com/FiercePharma ↗

Pharma trade outlet relaying FDA, deal, and exec-move newsflow in real time

Institutional pharma/biopharma journalism: breaks and relays

trader score
+0.46
hit rate
67%
mean α
+0.36%
signals 14d
8

Grade = how their written analysis reads (A best). Trader score = how their last-20 timestamped calls performed vs SPY.

Their picks, scored

Across their last 6 scored bets: 67% hit rate, +0.36% mean alpha, trader score +0.46. Their last-14d mentions, direction-adjusted, have moved -4.5% since posting (mean over 5 mentions with price data).

Recent signals8receipts included
date (PT)tickerauthorsentwhat they saidsince thenreceipt
2026-10-15·@FiercePharma·NorthStar Medical Technologies partners with Quarkmed to expand actinium-225 supply access in China.·
2026-10-15GILD@FiercePharma+0.10Gilead launched an HIV-prevention awareness campaign for Latino communities.-0.8%
2026-10-15LLY@FiercePharma+0.30New Omvoh analyses show patients meeting multiple IBD treatment goals after prior biologic failure.+1.7%
2026-10-14·@FiercePharma·Galderma announced a $1.5B acquisition of private Zo Skin Health.·
2026-10-14LQDA@FiercePharma-0.35An analyst characterizes United Therapeutics' result against Liquidia as a clear-cut win.+25.7%
2026-10-14UTHR@FiercePharma+0.35An analyst characterizes United Therapeutics' result against Liquidia as a clear-cut win.+8.8%
2026-10-08ARGX@FiercePharma-0.45Argenx discontinued a Vyvgart Hytrulo trial in Sjögren's disease.+6.7%
2026-10-07·@FiercePharma·Highlights drugmakers' efforts to capitalize on unprecedented consumer interest in GLP-1 therapies.·

Grade is our human read-worthiness rating; trader score is a rolling 20-bet hit-rate/alpha composite — different things, often disagreeing. “Since then” is direction-unaware in the table; the summary line above adjusts for which way they leaned.